EC Approves Ibrutinib Plus Chemoimmunotherapy +/- ASCT in Untreated MCL
The focus of management strategies has been redefined for Immune-Checkpoint Inhibitor Toxicities in Melanoma patients. Quality of treatment has taken precedence in current advancements.
The FDA has made a significant step in the fight against high-grade Glioma. They granted Fast Track Designation to SRN-101, an important medicine under scrutiny for its potential in recurring cases.
A Novel Small Molecule is stirring excitement in the medical community. Demonstrating early activity in pretreated Multiple Myeloma, it hints at promising developments in future therapeutics.
An in-depth comparison of Quality of Life outcomes was conducted between Protons and Photons in OPSCC, furthering our understanding of their differential impacts on patients.
The Prostate Cancer treatments are also under a magnifying glass. There are three key aspects of PSMA-Directed Imaging and Radioligand Therapy that professionals in the field need to be aware of.
